Finance News – Wegovy
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Weight-loss drugs may be covered by Medicare, Medicaid under experimental program
The experimental program could potentially reduce out-of-pocket expenses for patients by allowing Medicare and Medicaid to cover expensive GLP-1 medications used for weight managem...
Read Full Article →Novo Nordisk cuts sales forecasts for its once-blockbuster weight loss drugs
Novo Nordisk's lowered projections reflect ongoing challenges from increased competition and weaker global demand, which together are impacting the revenue potential of its weight...
Read Full Article →Wegovy maker warns of slower profits as rivals bite
The Danish pharmaceutical company producing Wegovy projects reduced profit growth due to increased competition from alternative weight loss drugs entering the market and impacting...
Read Full Article →Novo Nordisk shares plunge 23% on profit warning amid US weight-loss drug competition
The company experienced a significant decline in market value following a reduced profit forecast, reflecting increased challenges in the competitive landscape of weight-loss medic...
Read Full Article →Novo Nordisk issues profit warning as competition — legal and otherwise — hits Wegovy, Ozempic
Novo Nordisk lowered its forecast due to increasing challenges from various competitors, leading to a decline in its stock value and signaling potential impacts on the company's fu...
Read Full Article →Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its partnership with the company.
The termination of the collaboration between Hims & Hers and Novo Nordisk triggered a substantial decline in Hims & Hers’ share value, reflecting investor concerns about the compan...
Read Full Article →Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
Novo Nordisk’s medications associated with uncommon but severe eye issues may impact the company’s valuation, as emerging health technology firms continue to gain significant inves...
Read Full Article →Noom is offering smaller doses of compounded Wegovy for weight loss
By introducing reduced-strength compounded Wegovy, Noom aims to capture a broader customer base while addressing cost concerns in the expanding weight management industry.
Read Full Article →Wegovy firm unexpectedly forces boss to step down
The unexpected leadership change reflects the company's response to financial pressures and declining investor confidence amid ongoing difficulties in maintaining its market positi...
Read Full Article →Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
Novo Nordisk announced that its CEO, Lars Fruergaard Jørgensen, will resign following a significant decline in the company’s market value linked to challenges faced by its key diab...
Read Full Article →Novo Nordisk CEO to step down as Wegovy maker faces growing competition
The departure of the CEO at the Danish pharmaceutical company is expected to impact investor confidence as the firm navigates increased market rivalry and aims to sustain its finan...
Read Full Article →Ozempic maker Novo Nordisk boots CEO over stock-price fall
The departure of Novo Nordisk's CEO follows a decline in the company's market value, highlighting investor concerns about future financial performance in the competitive pharmaceut...
Read Full Article →This biotech’s stock rockets on oral obesity-drug partnership with Wegovy parent
The collaboration between Novo Nordisk and Septerna is expected to enhance their pipeline in obesity and diabetes therapies, potentially increasing market value and investor confid...
Read Full Article →Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
The superior results of Eli Lilly’s medication compared to Novo Nordisk’s in the recent trial may influence market dynamics and investor confidence within the competitive obesity t...
Read Full Article →Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit bea...
Despite reporting higher-than-anticipated first-quarter earnings, Novo Nordisk adjusted its 2025 revenue outlook downward due to slower demand for Wegovy, impacting overall financi...
Read Full Article →CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Starting July 1, Caremark will prioritize Wegovy on its formulary, improving accessibility for patients on its drug plans and potentially increasing the treatment's market presence...
Read Full Article →